GlycoT was awarded a Phase I SBIR

August 1, 2019

GlycoT was awarded a Phase I SBIR grant (1R43GM134816, $300,000) from NIH to further streamline its proprietary chemoenzymatic transglycosylation approach for antibodies and other glycoproteins. Such streamlines methods, provided in the form of commercial kits, can help general academic and industrial users to perform glycan-remodeling reactions. The streamlined approach can also be applied in scale-up preparation of homogenous glycoproteins with therapeutic potential.

Research and Development Collaborations
To request a quote for our products, customized service, investment opportunities, or if you have any general inquiry for our company click the start now button.
Learn More